Peter A. Schwartzman
Corporate Officer/Principal bei RADIUS HEALTH, INC.
Aktive Positionen von Peter A. Schwartzman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
RADIUS HEALTH, INC. | Corporate Officer/Principal | 06.10.2020 | - |
Investor Relations Kontakt | 06.10.2020 | - |
Karriereverlauf von Peter A. Schwartzman
Ehemalige bekannte Positionen von Peter A. Schwartzman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BlackRock Advisors LLC
BlackRock Advisors LLC Investment ManagersFinance BlackRock Advisors LLC is a SEC-registered investment advisor and mutual fund manager headquartered in New York City. The firm was founded in 1994 and is a subsidiary of BlackRock Capital Holdings, Inc., ultimately held by BlackRock, Inc. (NYSE: BLK). BlackRock Advisors manages assets for US-registered investment companies and 529 Plans. | Analyst-Festverzinsliche Wertpapiere | - | - |
Ausbildung von Peter A. Schwartzman
Trinity College (Connecticut) | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Analyst-Fixed Income | 1 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sektoral
Consumer Services | 3 |
Finance | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
BlackRock Advisors LLC
BlackRock Advisors LLC Investment ManagersFinance BlackRock Advisors LLC is a SEC-registered investment advisor and mutual fund manager headquartered in New York City. The firm was founded in 1994 and is a subsidiary of BlackRock Capital Holdings, Inc., ultimately held by BlackRock, Inc. (NYSE: BLK). BlackRock Advisors manages assets for US-registered investment companies and 529 Plans. | Finance |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Peter A. Schwartzman
- Erfahrung